Emergent Management of Guillain-Barre Syndrome

Back

Overview

Guillain-Barré syndrome (GBS) is a heterogeneous grouping of immune-mediated processes generally characterized by motor, sensory, and autonomic dysfunction. In its classic form, GBS is an acute inflammatory demyelinating polyneuropathy characterized by progressive symmetric ascending muscle weakness, paralysis, and hyporeflexia with or without sensory or autonomic symptoms; however, variants involving the cranial nerves or pure motor involvement are not uncommon.

Emergency department care of patients with GBS involves close monitoring of respiratory and cardiovascular status. Intubation may be indicated.

Labile autonomic dysfunction may complicate the use of vasoactive and sedative drugs. In severe cases, muscle weakness may lead to respiratory failure. A 2008 epidemiological study reported 2-12% mortality despite ICU management.[1]

Plasma exchange and intravenous immune globulin may be effective, but patients may require prolonged intubation or intensive care. After discharge, outpatient physical therapy and occupational therapy may be beneficial in helping patients with GBS to regain their baseline functional status.[2, 3, 4]

Approximately half of all patients who have had GBS experience long-term residual neuropathy affecting large- and medium-sized myelinated fibers.[5] Overall, patients who have had GBS patients seem to have a reduced quality of life and physical functioning.[6] In extremely rare cases, patients may experience recurrent GBS.[7, 8]

Among survivors of GBS, Khan et al found that the following factors were associated with poorer level of functioning and well-being[9] :

Outcome does not appear to correlate with the severity of disease at onset.[9, 6]

See also Guillain-Barré Syndrome and Pediatric Guillain-Barré Syndrome.

Patient education

For patient education information, see the Brain and Nervous System Center, as well as Guillain-Barré Syndrome.

ABCs, Intubation, and Monitoring

Prehospital care of patients with Guillain-Barré syndrome (GBS) requires careful attention to airway, breathing, and circulation (ABCs). Administration of oxygen and assisted ventilation may be indicated, along with establishment of intravenous access. Emergency medical services personnel should monitor for cardiac arrhythmias and transport expeditiously.

In the emergency department (ED), continuation of ABCs, IV, oxygen, and assisted ventilation may be indicated.[10] Intubation should be performed on patients who develop any degree of respiratory failure. Clinical indicators for intubation in the ED include hypoxia, rapidly declining respiratory function, poor or weak cough, and suspected aspiration. Typically, intubation is indicated when the forced vital capacity (FVC) is less than 15 mL/kg.[11]

Patients should be monitored closely for changes in blood pressure, heart rate, and arrhythmias. Treatment is rarely needed for tachycardia. Atropine is recommended for symptomatic bradycardia. Because of the lability of dysautonomia, hypertension is best treated with short-acting agents, such as a short-acting beta-blocker or nitroprusside. Hypotension from dysautonomia usually responds to intravenous fluids and supine positioning. Temporary pacing may be required for patients with second- and third-degree heart block.

Consult a neurologist if any uncertainty exists as to the diagnosis. Consult the ICU team for evaluation of need for admission to the unit.

Plasma Exchange and Immune Globulin

Only plasma exchange (PE) therapy and intravenous immune globulin (IVIG) have proven effective for Guillain-Barré syndrome (GBS). They may decrease autoantibody production and increase solubilization and removal of immune complexes. Both have been shown to shorten recovery time by as much as 50%. IVIG is easier to administer and has fewer complications than PE.[12, 13] The cost and efficacy of each are comparable.

Randomized trials in severe disease show that IVIG started within 4 weeks from onset hastens recovery as much as plasma exchange.[14, 12, 15, 16, 17] Combining PE and IVIG neither improved outcomes nor shortened illness duration.[18] IVIG has also been found safe and effective in the treatment of pediatric GBS.[18, 19]

Additionally, IVIG is the preferential treatment in hemodynamically unstable patients and in those unable to ambulate independently.[20, 18] Some evidence suggests that in select patients who do not respond initially to IVIG, a second dose may be beneficial.[21] However, this is not currently standard therapy and warrants further investigation.

Corticosteroids

Corticosteroids are ineffective as monotherapy.[22, 23, 24] According to moderate-quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome.[24] According to low-quality evidence, oral corticosteroids delay recovery.[15, 24] Diabetes requiring insulin was significantly more common and hypertension less common with corticosteroids.

Substantial evidence shows that IV methylprednisolone alone produces neither significant benefit nor harm.[24] In combination with IVIG, IV methylprednisolone may hasten recovery but does not significantly affect long-term outcome.[15, 25]

Investigational Agents

In an animal model, intravenous eculizumab was reported to prevent respiratory paralysis and the functional and morphological hallmarks of terminal motor neuropathy. Human studies have not been reported.[26]

Interferon beta was not associated with significant clinical improvement compared with controls in a small randomized control trial.[27] Mycophenolate mofetil, used as an adjunct therapy with IVIG, showed no benefit in a pilot study.[28]

Immune Adsorption

Immune adsorption is an alternative treatment for Guillain-Barré syndrome that is still in the early stages of investigation. A small prospective study reported no difference in outcome between patients treated with immunoadsorption and those treated with plasma exchange.[29]

In critically ill patients, a small German study reported that treatment with selective immune adsorption (SIA) seems to be safe and effective.[30] In comparison to treatment with SIA only, sequential therapy with IVIG was not more effective.[30]

Pain Management

Simple analgesics or nonsteroidal anti-inflammatory drugs may be tried but often provide inadequate analgesia.

Single, small randomized controlled trials support the use of gabapentin or carbamazepine in the intensive care unit for management during the acute phase of GBS.

Adjuvant therapy with a tricyclic antidepressant, tramadol, gabapentin, carbamazepine, or mexiletine may aid in the long-term management of neuropathic pain.[3]

Prevention of Thromboembolism

Venous thromboembolism is one of the major sequela of extremity paralysis. Time to development of deep vein thrombosis (DVT) or pulmonary embolism varies from 4-67 days following symptom onset.[3] Prophylaxis with gradient compression hose and subcutaneous low molecular weight heparin (LMWH) may dramatically reduce the incidence of venous thromboembolism.[3]

True gradient compression stockings (30-40 mm Hg or higher) are highly elastic and provide compression along a gradient that is highest at the toes and gradually decreases to the level of the thigh. This reduces capacity venous volume by approximately 70% and increases the measured velocity of blood flow in the deep veins by a factor of 5 or more.

The ubiquitous white stockings known as antiembolic stockings or thromboembolic disease (TED) hose produce a maximum compression of 18 mm Hg and rarely are fitted in such a way as to provide adequate gradient compression. They have not been shown to be effective as prophylaxis against thromboembolism.

Inpatient Care

Admission to the ICU should be considered for all patients with labile dysautonomia, a forced vital capacity of less than 20 mL/kg, or severe bulbar palsy.[3] Any patients exhibiting clinical signs of respiratory compromise, in any degree, also should be admitted to an ICU.[3] In addition to those criteria used for intubation in the ED, Medical Research Council sum score as well as bulbar weakness have been reported to be predictive of requiring inpatient mechanical ventilation.[31]

The risk of sepsis and infection can be decreased by use of minimal sedation, frequent physiotherapy, and mechanical ventilation with positive end-expiratory pressure where appropriate.[3] Transfer may be appropriate if a facility does not have the proper resources to care for patients who may require prolonged intubation or prolonged intensive care.

The risk of deep venous thrombosis (DVT) and pulmonary embolism may be minimized by administration of heparin or a low molecular weight heparin and intermittent pneumatic compression devices.[3]

The use of cardiac telemetry and pacing in the case of severe bradycardia may help to reduce the risk of cardiac morbidity and mortality.[3]

Pain may be relieved by frequent passive limb movements, gentle massage, frequent position changes, and use of carbamazepine and gabapentin.[32, 3] Narcotics should be used judiciously because patients may already be at risk for ileus.[3]

Author

Andrew C Miller, MD, Fellow, Department of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center (UPMC); Attending Physician, Department of Emergency Medicine, UPMC St Margaret's Hospital

Disclosure: Nothing to disclose.

Coauthor(s)

Razi M Rashid, MD, MPH, Resident Physician, Department of Neurology, Northwestern University Hospital

Disclosure: Nothing to disclose.

Richard H Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Disclosure: Nothing to disclose.

Specialty Editors

Edward A Michelson, MD, Associate Professor, Program Director, Department of Emergency Medicine, University Hospital Health Systems of Cleveland

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Steven C Dronen, MD, FAAEM, Chair, Department of Emergency Medicine, LeConte Medical Center

Disclosure: Nothing to disclose.

References

  1. Alshekhlee A, Hussain Z, Sultan B, et al. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. Apr 29 2008;70(18):1608-13. [View Abstract]
  2. Bersano A, Carpo M, Allaria S. Long term disability and social status change after Guillain-Barre syndrome. J Neurol. 2006;253(2):214-8. [View Abstract]
  3. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with guillain-barre syndrome. Arch Neurol. Aug 2005;62(8):1194-8. [View Abstract]
  4. Mullings KR, Alleva JT, Hudgins TH. Rehabilitation of Guillain-Barré syndrome. Dis Mon. May 2010;56(5):288-292. [View Abstract]
  5. Dornonville de la Cour C, Jakobsen J. Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome. Neurology. Jan 2005;64(2):246-53. [View Abstract]
  6. Rudolph T, Larsen JP, Farbu E. The long-term functional status in patients with Guillain-Barre syndrome. European Journal of Neurology. Dec 2008;15(12):1332-7. [View Abstract]
  7. Das A, Kalita J, Misra UK. Recurrent Guillain Barre' syndrome. Electromyogr Clin Neurophysiol. Mar 2004;44(2):95-102. [View Abstract]
  8. Roper TA, Alani SM. Recurrent Guillain-Barre syndrome: lightning does strike twice. Br J Hosp Med. Apr 19-May 2 1995;53(8):403-7. [View Abstract]
  9. Khan F, Pallant JF, Ng L, et al. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. Jul 2010;[View Abstract]
  10. McGillicuddy DC, Walker O, Shapiro NI, et al. Guillain-Barre syndrome in the emergency department. Ann Emerg Med. Apr 2006;47(4):390-3. [View Abstract]
  11. Wijdicks EF, Henderson RD, McClelland RL. Emergency intubation for respiratory failure in Guillain-Barre syndrome. Arch Neurol. Jul 2003;60(7):947-8. [View Abstract]
  12. Koski CL, Patterson JV. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs. May-Jun 2006;29(3 Suppl):S21-8. [View Abstract]
  13. Shahar E. Current therapeutic options in severe Guillain-Barre syndrome. Neuropharmacol. Jan-Feb 2006;29(1):45-51. [View Abstract]
  14. [Best Evidence] Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. Jun 16 2010;6:CD002063. [View Abstract]
  15. [Best Evidence] Hughes RA, Swan AV, van Koningsveld R. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. Apr 19 2006;2:CD001446. [View Abstract]
  16. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. May 19 2004;291(19):2367-75. [View Abstract]
  17. Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion. Oct 2005;45(10):1640-57. [View Abstract]
  18. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. Sep 23 2003;61(6):736-40. [View Abstract]
  19. Yata J, Nihei K, Ohya T, et al. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Int. Oct 2003;45(5):543-9. [View Abstract]
  20. Lindenbaum Y, Kissel JT, Mendell JR. Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Clin. Feb 2001;19(1):187-204. [View Abstract]
  21. van Doorn PA, Kuitwaard K, Walgaard C, et al. IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol. May 2010;30 Suppl 1:S74-78. [View Abstract]
  22. Winer JB. Guillain Barre syndrome. Mol Pathol. Dec 2001;54(6):381-5. [View Abstract]
  23. Winer JB. Treatment of Guillain-Barré syndrome. QJM. Nov 2002;95(11):717-21. [View Abstract]
  24. [Best Evidence] Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. Feb 2010;2:CD001446. [View Abstract]
  25. Odaka M, Tatsumoto M, Hoshiyama E, et al. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barre syndrome. Eur Neurol. 2005;53(4):194-6. [View Abstract]
  26. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. May 2008;131:1197-208. [View Abstract]
  27. Pritchard J, Gray IA, Idrissova ZR, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology. Nov 2003;61(9):1282-1284.
  28. Garssen MP, van Koningsveld R, van Doorn PA, et al. Treatment of Guillain-Barre syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry. Sep 2007;78(9):1012-3. [View Abstract]
  29. Seta T, Nagayama H, Katsura K. Factors influencing outcome in Guillain-Barre Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. Oct 2005;107(6):491-6. [View Abstract]
  30. Galldiks N, Dohmen C, Neveling M, et al. Selective Immune Adsorption Treatment of Severe Guillain Barré Syndrome in the Intensive Care Unit. Neurocrit Care. Jul 30 2009;[View Abstract]
  31. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. Jun 2010;67(6):781-787. [View Abstract]
  32. Pandey CK, Raza M, Tripathi M, et al. The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit. Anesth Analg. Jul 2005;101(1):220-5, table of contents. [View Abstract]